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Abstract
Objective To assess the efficacy of caudal epidural steroid or saline
injection in chronic lumbar radiculopathy in the short (6 weeks),
intermediate (12 weeks), and long term (52 weeks).
Design Multicentre, blinded, randomised controlled trial.
Setting Outpatient multidisciplinary back clinics of five Norwegian
hospitals.
Participants Between October 2005 and February 2009, 461 patients
assessed for inclusion (presenting with lumbar radiculopathy >12 weeks).
328 patients excluded for cauda equina syndrome, severe paresis,
severe pain, previous spinal injection or surgery, deformity, pregnancy,
ongoing breast feeding, warfarin therapy, ongoing treatment with
non-steroidal anti-inflammatory drugs, body mass index >30, poorly
controlled psychiatric conditions with possible secondary gain, and
severe comorbidity.
Interventions Subcutaneous sham injections of 2 mL 0.9% saline,
caudal epidural injections of 30 mL 0.9% saline, and caudal epidural
injections of 40 mg triamcinolone acetonide in 29 mL 0.9% saline.
Participants received two injections with a two week interval.
Main outcome measures Primary: Oswestry disability index scores.
Secondary: European quality of life measure, visual analogue scale
scores for low back pain and for leg pain.
Results Power calculations required the inclusion of 41 patients per
group. We did not allocate 17 of 133 eligible patients because their
symptoms improved before randomisation. All groups improved after
the interventions, but we found no statistical or clinical differences
between the groups over time. For the sham group (n=40), estimated
change in the Oswestry disability index from the adjusted baseline value
was −4.7 (95% confidence intervals −0.6 to −8.8) at 6 weeks, −11.4
(−6.3 to −14.5) at 12 weeks, and −14.3 (−10.0 to −18.7) at 52 weeks.
For the epidural saline intervention group (n=39) compared with the
sham group, differences in primary outcome were −0.5 (−6.3 to 5.4) at
6 weeks, 1.4 (−4.5 to 7.2) at 12 weeks, and −1.9 (−8.0 to 4.3) at 52
weeks; for the epidural steroid group (n=37), corresponding differences
were −2.9 (−8.7 to 3.0), 4.0 (−1.9 to 9.9), and 1.9 (−4.2 to 8.0). Analysis
adjusted for duration of leg pain, back pain, and sick leave did not change
this trend.
Conclusions Caudal epidural steroid or saline injections are not
recommended for chronic lumbar radiculopathy.
Trial registration Current Controlled Trials ISRCTN No 12574253.
Introduction
Chroniclumbarradiculopathyisdefinedasaclinicalsyndrome
of back and leg pain accompanied by sensory, reflex, or motor
deficits in a nerve root distribution lasting for more than 12
weeks.
1-4 The lifetime prevalence of lumbar radiculopathy has
beenreportedtobe5.3%inmenand3.7%inwomen.
5 6Lumbar
radiculopathy due to a prolapsed disc resolves spontaneously
in 23-48% of patients, but up to 30% will still have pronounced
symptoms after one year, 20% will be out of work, and 5-15%
will undergo surgery.
7-10
Epidural steroid injections for lumbar radiculopathy have been
usedsince1953.
11Alongwithmechanicalcompressionofnerve
roots, lumbar radiculopathy can be triggered by different
proinflammatory chemical agents,
12-15 causing ectopic neuron
firing.
16 Steroids injected into the epidural space or around the
affected nerve root are thought to inhibit these inflammatory
mediators.However,thereisconflictingevidenceforapotential
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Research
RESEARCHbenefit of epidural steroid injections.
17-21 Some studies have
shown a moderate short term benefit,
18-25 whereas others have
shown little difference between epidural steroid and placebo
injections.
26-28Studiescomparingepiduralsteroidinjectionswith
epidural saline or local anaesthetic injections have shown less
benefitfromsteroids
26 29 30thanthosecomparingepiduralsteroid
injections with sham or soft tissue injections.
22 23 31 32
Furthermore, recent studies have concluded that epidural local
anaesthetic or saline alone could have a positive effect by
itself.
33 34
At the one year follow-up after epidural steroid injection,
improvement of pain and disability has been reported for 36%
to43%ofthepatients.
25 35However,thisoutcomedoesnotdiffer
greatly from the natural history of the disease.
36 The true effect
of epidural steroid injections might be to reduce radicular pain
before natural recovery occurs.
37 Despite the lack of evidence
for long term efficacy, the use of epidural steroid injection in
the United States increased from 553 to 2055 per 100 000
patients from 1994 to 2001.
38 In the United Kingdom, epidural
steroid injection for lumbar radiculopathy was one of the most
common therapeutic spine injection procedures in 2002-03.
1
We aimed to assess the effects of caudal epidural steroid and
saline injections compared with subcutaneous sham injections
in patients with chronic radiculopathy, by measuring
improvements in physical function, health related quality of
life, and pain at short term (6 weeks), intermediate term (12
weeks), and long term (52 weeks) follow-up.
Methods
We used a subcutaneous sham injection to control for the
possibleeffectofahighvolumesalineinjectedintotheepidural
space,andwecomparedepiduralsteroidinjectionswithepidural
saline injections to clarify the effect of steroids.
Participants
We referred patients with lumbar radiculopathy from the
catchment area of the University Hospital of North Norway, St
Olavs University Hospital, Levanger Hospital, Nordland
Hospital, and Buskerud Hospital (population 1 146 076). The
general practitioners, neurosurgeons, orthopaedic surgeons,
neurologists,manualphysiotherapists,andchiropractorsworking
in these areas were informed by letter about the trial.
The inclusion criteria included unilateral lumbar radiculopathy
lasting for more than 12 weeks. The intensity of the leg pain,
radiatingfromthebacktobelowtheknee,hadtobecomparable
or worse than the back pain. We assessed eligible patients aged
between 20 and 60 years consecutively for inclusion and
obtained written informed consent. The clinical examination
followedapreparedstudytemplatetodecidewhetherthepatient
had a lumbar radiculopathy and to determine the most probable
nerve root affected. Trained neurologists or specialists in
physical medicine and rehabilitation in cooperation with a
physiotherapist undertook the inclusion examinations. We
excluded328patientspresentingwithacaudaequinasyndrome,
severeparesis,severepain,historyofspinalinjectionorsurgery,
deformity,pregnancy,ongoingbreastfeeding,warfarintherapy,
ongoing treatment with non-steroidal anti-inflammatory drugs,
body mass index of more than 30, poorly controlled psychiatric
conditionswithpossiblesecondarygain,orseverecomorbidity.
Twenty four (7%) excluded patients underwent back surgery.
We did magnetic resonance imaging (n=110) or computed
tomography (n=6) in all included patients. Experienced
radiologists at each centre assessed the images and produced a
written report for the investigators. Inclusion in the trial was
not dependent on the results from the magnetic resonance
imaging and computed tomography. The results did not have
to correspond with those from the clinical examination. To be
included, the patients had to have clinically proved
radiculopathy. We excluded patients who showed severe
intraspinal pathology (large disc herniations occupying more
than50%ofthespinalcanal,spinalstenosis,tumours,bleeding,
dural fistula, synovial cysts, or dysraphia).
Each patient completed self administered questionnaires
including the outcome measures, which were identical at
baseline and follow-up. The baseline questionnaires contained
additional questions about demographics, education, duration
of pain, work status, avoidance of movement owing to fear of
pain,medication,andlifestyleissues.Wealsomonitoredclinical
signsoflumbarradiculopathy,needforphysiotherapyorsurgery
during follow-up, whether the patient perceived benefit of the
intervention, beliefs about fear avoidance,
39 and working
capability at each follow-up. All patients received standardised
oral and written information about spine anatomy and function
at baseline and follow-up. Patients were encouraged to engage
in physical activity,
40-43 and received an information brochure.
44
Patients using non-steroidal anti-inflammatory drugs were told
to stop this medical treatment.
Randomisation
The clinical research centre at the University Hospital of North
Norway used a computer generated block scheme for
randomisation, stratified by intervention hospital. The centre
was contacted by telephone on the day of intervention. The
individuals undertaking the randomisation did not take any
further part in the trial.
Outcomes
The Oswestry disability index was the primary outcome
measure. The Oswestry disability index questionnaire contains
10 questions on limitations of activities to daily living. Each
variablewasratedona0-5pointscale,addedup,andconverted
intoapercentagefunctionalscorerangingfrom0to100(where
0=no disability).
45-47
We assessed secondary outcome measures by the European
quality of life measure, the visual analogue scale for low back
pain, and the visual analogue scale for leg pain. The European
quality of life measure is a generic and preference weighted
measure of health related quality of life. It evaluates five
dimensions: mobility, self care, activities of daily life, pain, and
anxietyordepression.Foreachdimension,thepatientdescribes
three possible levels of problems (none, mild to moderate, and
severe).Thisdescriptivesystemcontains243(35)combinations
or index values for health states.
48 We used the value set from
the main survey of the EuroQol group,
49 which has been
validated for patients with lumbar radiculopathy.
50 Total score
rangeisfrom−0.594to1,where1correspondstoperfecthealth
and 0 to death. Negative values are considered to be worse than
death.
48 The intensity of leg pain and low back pain was
indicated on a horizontal 100 mm visual analogue scale (where
0=no pain).
50 51
Follow-up
A blinded physiotherapist and doctor followed up patients at 6,
12, and 52 weeks. Use of physiotherapy was recorded during
follow-up, but was not routinely offered to the patients. During
thestudy,surgeonsindependentlyassessedtheneedforsurgical
treatment among patients with increasing pain or paresis.
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RESEARCHWe used a global question on a four point Likert scale to
measure the benefit of the intervention at each follow-up.
52 The
patients were asked: “What benefit of the treatment have you
had?” The response alternatives were: “much”, “some”, “no
benefit”, and “I am worse”. We recoded these variables into a
dichotomous outcome with “much” and “some” benefit
representing that the patients had benefited from the treatment.
Intervention
A standardised referral letter for the intervention contained
information about the patient’s cardiac and pulmonary status,
medication,andallergies,butdidnotincludeinformationabout
back pain and radiculopathy. There were three intervention
groups. Group 1 received subcutaneous sham injections of 2
mL 0.9% saline, superficial to the sacral hiatus and not into the
spinal canal. Group 2 received caudal epidural injections of 30
mL 0.9% saline. Group 3 received caudal epidural injections of
40 mg triamcinolone acetonide in 29 mL 0.9% saline. All three
intervention groups received two injections with a two week
interval; the second injection was cancelled if spontaneous
recovery had occurred between inclusion and the first
intervention.
An experienced anaesthesiologist gave the injections and
followed a set template.
53 54 Anatomical landmarks were used
to identify the sacral hiatus. In addition, use of an ultrasound
machine (Honda Diagnostic Scanner HS-2000 Cine, Honda
Electronics Co) capable of examining musculoskeletal tissues
with a 10 MHz real time linear array ultrasound transducer
increased the precision of the injections.
55-57
Blinding
We ensured that the patients, outcome assessors, and care
providers were blinded during the study period; they were all
unaware of the randomisation and intervention given by the
anaesthesiologists. The anaesthesiologist giving the injections
wasnotblindedbecauseinclusionofasubcutaneousshamgroup
made this impossible.
58 The injection products were concealed
from the patients, and the anaesthesiologists were instructed
not to discuss the injection procedure or the products used with
the patients.
Statistical analysis
We did sample size calculations for a multicentre multilevel
longitudinalmodelwithrepeatedmeasurementsontheprimary
continuous outcome variable, the Oswestry disability index.
The study was powered to detect an assumed clinically
significant difference between one of the two injection groups
and the sham group of 10 points on average over time. Based
on a standard deviation of 18, a significance level of 5%, a
power of 80%, and a correlation coefficient of 0.6 between the
three follow-up measurements, the number of patients in each
intervention group needed to be 37. Adjusting for losses to
follow-upandwithdrawalsfromthestudy,wesettheminimum
number of patients to be included in each group to be 41.
The analyses for all outcome measures used all available data
onanintentiontotreatbasis.Weanalysedallpatientsaccording
to the group to which they were allocated, regardless of
crossovers, surgery, withdrawal from the study, or loss to
follow-up.Intheanalysisofoutcomesinpatientswhowithdrew
or were lost to follow-up, we used the available data in the
mixed model analysis. We analysed data with Stata 11.0
(StataCorp) and SPSS 17.0 (SPSS Inc).
Descriptive statistics were presented as means with standard
deviations, means with confidence intervals, or numbers with
percentages. We assessed groups at baseline by analysis of
variance for continuous variables and by Pearson χ
2 tests for
categorical variables.
Weusedlinearmixedmodelstoassessdifferencesintimetrends
between the treatment groups for the primary and secondary
outcomemeasures.
59Weaddedtimetothemodelasacategorical
variable represented by dummy variables to analyse the
differences between the groups at different time points. In all
mixed model analyses, we made a crude adjustment for the
baselinevaluesoftheparticularoutcomevariable.Insecondary
analysis, we made additional adjustments for any duration of
back pain, leg pain, and sick leave before inclusion. All tests
were two sided using a significance level of 5%.
Results
Between October 2005 and February 2009, 461 patients were
assessed for inclusion, and 133 were included in the study (48,
University Hospital of North Norway; 20, Nordland Hospital;
26, Levanger Hospital; 27, St Olavs University Hospital; 12,
Buskerud Hospital). Of the 328 excluded patients, three
exclusions(1%)werebecauseofintraspinalpathologyandeight
(2%) because of psychiatric conditions. Seventeen patients did
not undergo randomisation because their symptoms improved
between assessment and randomisation (fig 1⇓). Therefore, we
included 116 (25%) patients in the intention to treat analysis.
Afterrandomisation,weexcludedanotherfivepatientsbecause
of spontaneous improvement before the first injection (fig 1).
We analysed 37 patients in the caudal epidural steroid group,
39inthecaudalepiduralsalinegroup,and40intheshamgroup
(fig 1). We followed up 109 patients at 6 weeks, 105 at 12
weeks, and 99 at 52 weeks (table 1⇓). We did not record any
crossovers between the treatment groups. The distribution
between treatment groups within each hospital was roughly
equal, and adjustment for hospital did not change these results
(table 2⇓). Table 3⇓ shows baseline characteristics of the study
population. We did not detect any significant differences
betweentreatmentgroups,exceptforasignificantlyhigherrate
ofthepresenceofankletendonreflexdifferenceamongpatients
in the caudal epidural saline group.
The median interval between inclusion and randomisation to
the first injection was 3 (range 0-17) weeks, and the median
interval between the two injections was 3 (2-5) weeks. This
variation was caused by logistical and patient related factors
affected by long travelling distance in rural Norway. We did
not detect any difference in median time interval between
inclusionandrandomisationbetweenthegroups.Weregistered
no serious complications from the injections. Six (5%) patients
experienced local pain during the first injection and declined
thesecondinjection,therebydiscontinuingtheintervention(fig
1). The treatment groups did not differ significantly for the
primary and secondary outcomes. Figures 2-5⇓⇓⇓⇓show the
between group differences for the primary and secondary
outcome variables from baseline to follow-up.
For both the primary and secondary outcome measures at 6, 12,
and 52 week follow-up, we did not see any significant
differences between the epidural injection groups and the sham
group.Furthermore,theobserveddifferenceswerenotclinically
important.
60 The estimated change in the Oswestry disability
index from the adjusted baseline value for the sham group was
−4.7 (95% confidence intervals −0.6 to −8.8) at 6 week
follow-up,−11.4(−6.3to−14.5)at12weeks,and−14.3(−10.0
to−18.7)at52weeks.Theobservedbetweengroupdifferences
at 6, 12, and 52 week follow-up between the epidural injection
groupsandtheshamgroupwerenotclinicallyimportant.These
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RESEARCHresults did not change after we adjusted for both the baseline
scores and the duration of leg pain, low back pain, and sick
leave (tables 4⇓ and 5⇓).
Ancillary analysis
Fear avoidance belief scores decreased significantly from
baseline to the 52 week follow-up in all three groups (P<0.001)
but did not differ significantly between the groups (table 6⇓).
We did not find a significant reduction in the use of pain relief
medication from baseline to the 6 week follow-up, nor did we
recordanysignificantdifferencebetweentheinterventiongroups
in the use of paracetamol (P=0.26), non-steroidal
anti-inflammatorydrugs(P=0.45),ormorphine(P=0.70)(table
7⇓).
Between baseline and 52 week follow-up, we detected a
significant reduction in patients receiving sickness benefit in
the sham group (P=0.01) but not in either of the epidural
injectiongroups.However,therewerenosignificantdifferences
between the groups (P=0.61). At the 52 week follow-up, 28
(28%) patients received sickness benefit: 7 (22%) in the sham
group, 10 (30%) in the epidural saline group, and 11 (32%) in
the epidural steroid group.
During follow-up, 41 (13%) patients had physiotherapy: 12
(11%) at 6 weeks, 18 (17%) at 12 weeks, and 11 (11%) at 52
weeks, with no significant differences between the groups
(P=0.69). Fifteen (15%) patients had back surgery at the 52
week follow-up: one (1%) in the epidural steroid group, six
(6%) in the epidural saline group, and eight (8%) in the sham
group, with no significant differences between the groups
(P=0.07).
At baseline, all patients had clinically verified lumbar
radiculopathy(table1).At52weekfollow-up,27(27%)patients
stillhadalumbarradiculopathy,withnosignificantdifferences
seen between the groups (P=0.95). At 52 week follow-up, 49
(50%) patients stated that they had received “much” or “some”
benefit from the treatment, with no significant differences seen
between the groups (P=0.81).
Discussion
This randomised controlled trial compared caudal epidural
steroid or saline injections with subcutaneous sham injections.
Theresultsconfirmthenullhypothesisthattreatmentofchronic
lumbar radiculopathy with caudal epidural injection of steroids
or isotonic saline has no clinically important effect. We did not
find any significant differences between the treatment groups
in need of physiotherapy or surgery and the patients receiving
sickness benefit. We expected fear avoidance belief scores to
belowatbaselineandtofallduringfollow-up,becausepatients
were informed about the favourable prognosis of the lumbar
radiculopathy and were repeatedly encouraged to stay active.
Comparison with existing literature
There is conflicting evidence on whether epidural steroid
injections are efficacious,
61-63 and if so, what volume,
composition, or concentration of injection is best.
29 53 64-70 Two
randomisedstudiesfoundthattransforaminalsteroidinjections,
which deposit the medication directly over the affected nerve
roots, are more effective than caudal epidural steroid injections
in the short term.
63 71 We did not address this issue in our study.
Four randomised placebo controlled trials published between
1971 and 2009 with at least 12 months’ follow-up, including
between 23 and 183 participants, found no long term effect of
caudal epidural steroid injections.
29 30 32 33 72 One study showed
apositiveeffectofcaudalepiduralsteroidinjection.
72However,
the reported effect size (change in Oswestry disability index
score of 8.1 points) was smaller than what is considered to be
the minimal clinically significant difference.
43
High volumes of epidural solutions have been thought to clear
ordilutelocallyconcentratedchemicalirritantsaroundthespinal
nerveroots.
29 72Inourstudy,theeffectofahighvolume,caudal
epidural saline injection did not differ from a sham injection.
Our results suggest that the effect attributed to isotonic saline
probably reflects the spontaneous, natural course of lumbar
radiculopathy.
73
Strengths and limitations
This multicentre randomised controlled study was designed to
determinewhetherhighvolume,epiduralsalineinjectionsalone
orepiduralsalineinjectionsincombinationwithepiduralsteroid
could benefit patients with longstanding radiculopathy. The
study population was homogeneous with low psychosocial
strain. We carefully selected patients on the basis of clinical
criteria and not on strict magnetic resonance imaging findings.
This method accords with how epidural steroid injections are
used in daily clinical practice, improving the external validity
of our study. We used the caudal epidural injection technique
withultrasoundguidingtoimprovetheprecision.However,we
did not use contrast to visualise where the medication spread.
The use of large volumes (30 mL) for the epidural injections
ensured sufficient spread of the medication, reducing the need
for radiography during the injection procedure.
Our power calculation required inclusion of 41 patients in each
group to detect a 10 point between group difference for the
primary outcome measure. We did not reach this goal because
of rapid improvement in 17 patients between inclusion and
randomisation.Therefore,thestudywasslightlyunderpowered,
with four patients missing from the epidural steroid group, two
from the epidural saline group, and one from the sham group.
However, the study showed no trend towards any group
difference after 12 months. We therefore consider it highly
unlikely that a larger study population would have affected the
results. Furthermore, the patients in our study had longlasting
symptomsofradiculopathy(range26-57weeks),andourresults
might not be as relevant for patients with radiculopathy of
shorter duration.
Low efficacy, under-dosage, and a dilution effect due to the
high volumes injected could have influenced the effect of the
caudal epidural steroid injection in our study. The most
commonlyusedsteroidsforepiduralinjectionsaretriamcinolone
acetonide, betamethasone, and methylprednisolone. One study
compared triamcinolone and betamethasone and favoured
triamcinolone.
74 When given in equivalent doses, the efficacy
ofthesethreesteroidsisgenerallyconsideredtobecomparable.
22
In one study, researchers also used triamcinolone to compare
the effect of lumbar epidural steroid injection with placebo.
22
They gave three 80 mg injections over nine weeks (total dose
240mg),whereasweusedtwo40mginjectionsovertwoweeks
(totaldose80mg).Theobservedeffectsfromthepreviousstudy
did not differ from our results. It is therefore unlikely that we
could have improved the treatment effects by using another
steroid, or by increasing the dose of triamcinolone.
75
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RESEARCHWhat is already known on this topic
Clinical studies indicate that epidural steroid and saline injections might reduce pain due to acute lumbar radiculopathy
in the short term, but the middle term and long term effects are unknown
What this study adds
Neither caudal epidural steroid injections nor caudal epidural saline injections are effective for chronic lumbar
radiculopathy and are not recommended as an adjunct to recovery in patients whose symptoms have extended beyond
12 weeks
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RESEARCHTables
Table 1| Number (%) of patients at follow-up, by randomisation group
Total no (n=116) Caudal epidural steroid group (n=37) Caudal epidural saline group (n=39) Sham group (n=40) Follow-up
109 (94) 37 (100) 35 (90) 37 (93) 6 weeks
105 (91) 34 (92) 35 (90) 36 (90) 12 weeks
99 (85) 34 (92) 33 (85) 32 (80) 52 weeks
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RESEARCHTable 2| Number of patients at follow-up, by randomisation group
Total no Caudal epidural steroid group Caudal epidural saline group Sham group Follow-up hospital/week
University Hospital of North Norway
38 13 10 15 6
36 12 10 14 12
34 12 9 13 52
Nordland Hospital
26 8 10 8 6
18 6 6 6 12
17 5 6 6 52
Levanger Hospital
26 8 10 8 6
23 6 10 7 12
23 7 10 6 52
St Olavs University Hospital
19 7 7 5 6
19 7 6 5 12
17 7 5 5 52
Buskerud Hospital
9 3 3 3 6
13 3 3 4 12
5 3 3 2 52
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RESEARCHTable 3| Baseline characteristics of study population with chronic lumbar radiculopathy
Caudal epidural steroid group
(n=37)
Caudal epidural saline group
(n=39) Sham group (n=40)
40.1 (10.0) 42.8 (11.6) 42.8 (9.2) Mean (SD) age (years)
20 (54) 24 (62) 24 (60) Male sex
26.7 (4.5) 26.1 (3.6) 26.0 (3.3) Mean (SD) body mass index (kg/m²)
21 (57) 18 (46) 19 (47) Physically demanding work
25 (68) 26 (67) 22 (55) Received sickness benefit*
20.1 (37.6) 21.3 (32.7) 14.0 (32.8) Mean (SD) duration of sick leave (weeks)
42.5 (62.6) 57.1 (158.0) 26.7 (22.4) Mean (SD) duration of leg pain (weeks)
50.4 (64.3) 63.1 (157.8) 46.6 (86.3) Mean (SD) duration of back pain (weeks)
Use of analgesics
11 (30) 9 (23) 13 (33) Paracetamol
10 (27) 4 (10) 6 (15) NSAID
9 (24) 7 (18) 6 (15) Morphine
18 (49) 23 (59) 21 (53) Positive straight leg raising test†
29 (78) 23 (59) 31 (78) Dermatomal sensory loss
32 (87) 31 (80) 31 (78) Dermatomal muscle weakness
6 (16) 9 (23) 6 (15) Knee tendon reflex difference
10 (27) 24 (62) 13 (33) Ankle tendon reflex difference‡
Clinically suspected level of lumbar radiculopathy
1 (3) – – L2-L3
2 (5) 2 (5) 3 (8) L3-L4
14 (38) 11 (28) 12 (30) L4-L5
20 (54) 26 (67) 25 (63) L5-S1
MRI or CT findings
– 1 (3) – Normal
– – 1 (3) Disc protrusion
26 (70) 23 (59) 24 (60) Disc herniation
11 (30) 14 (36) 14 (35) Disc sequestration
– 1 (3) 1 (3) Recess stenosis
23.5 (20.5 to 26.5) 25.0 (21.9 to 28.1) 21.6 (17.9 to 25.3) Mean (95% CI) FABQ work
11.9 (10.2 to 13.6) 13.5 (12.1 to 14.9) 13.0 (11.3 to 14.7) Mean (95% CI) FABQ physical activity
32.5 (28.6 to 36.4) 31.4 (26.9 to 35.9) 26.3 (22.0 to 30.6) Mean (95% CI) Oswestry disability index
0.54 (0.45 to 0.62) 0.46 (0.35 to 0.56) 0.54 (0.47 to 0.56) Mean (95% CI) EQ5D
50.1 (42.5 to 57.7) 53.5 (45.6 to 61.3) 48.3 (39.6 to 56.9) Mean (95% CI) VAS leg pain
46.8 (39.0 to 54.6) 49.6 (40.3 to 58.2) 46.3 (39.2 to 54.1) Mean (95% CI) VAS back pain
Data are number (%) unless stated otherwise. SD=standard deviation; CI=confidence intervals; NSAID=non-steroidal anti-inflammatory drug; MRI=magnetic
resonance imaging; CT=computer tomography; FABQ=fear avoidance beliefs questionnaire; EQ5D=European quality of life measure; VAS=visual analogue scale.
*On full or partial sick leave, government funded rehabilitation, or disability pension.
†When radiating leg pain >60° elevated leg.
‡P=0.004 difference.
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RESEARCHTable 4| Estimated differences in Oswestry disability index score between epidural injection groups and sham group at follow-up
Difference (95% confidence intervals) at follow-up
52 weeks 12 weeks 6 weeks
Crude analysis*
−1.9 (−8.0 to 4.3) 1.4 (−4.5 to 7.2) −0.5 (−6.3 to 5.4) Epidural saline injection
1.9 (−4.2 to 8.0) 4.0 (−1.9 to 9.9) −2.9 (−8.7 to 3.0) Epidural steroid injection
Adjusted analysis†
−2.6 (−8.9 to 3.6) 1.5 (−4.5 to 7.5) −0.6 (−6.6 to 5.4) Epidural saline injection
1.7 (−4.5 to 7.8) 3.7 (−2.3 to 9.7) −3.2 (−9.1 to 2.7) Epidural steroid injection
Data based on mixed model analysis with sham group as reference.
*Analysis adjusted for baseline values.
†Analysis adjusted for duration of leg pain, back pain, and sick leave.
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RESEARCHTable 5| Estimated differences in secondary outcome measures between epidural injection groups and sham group at follow-up
Difference (95% confidence intervals) at follow-up
52 weeks 12 weeks 6 weeks
Leg pain
Crude analysis*
3.1 (−9.6 to 15.8) 2.5 (−9.6 to 14.6) 3.2 (−9.1 to 15.5) Epidural saline injection
−0.2 (−12.9 to 12.5) 11.2 (−1.0 to 23.4) −1.3 (−13.3 to 10.7) Epidural steroid injection
Adjusted analysis†
0.5 (−12.4 to 13.4) 1.7 (−10.7 to 14.0) 2.7 (−9.8 to 15.2) Epidural saline injection
−1.4 (−14.1 to 11.4) 10.0 (−2.2 to 22.3) −2.6 (−14.6 to 9.4) Epidural steroid injection
Low back pain
Crude analysis*
−2.0 (−14.3 to 10.2) −7.8 (−19.3 to 3.8) −5.0 (−16.7 to 6.7) Epidural saline injection
0.0 (−12.1 to 12.2) 6.6 (−5.0 to 18.2) −4.8 (−16.2 to 6.6) Epidural steroid injection
Adjusted analysis†
−4.1 (−16.5 to 8.4) −9.3 (−21.2 to 2.5) −6.9 (−18.8 to 5.1) Epidural saline injection
−1.4 (−13.6 to 10.8) 5.1 (−6.5 to 16.8) −6.4 (−17.9 to 5.1) Epidural steroid injection
European quality of life measure
Crude analysis*
−0.01 (−0.12 to 0.11) −0.05 (−0.17 to 0.06) −0.02 (−0.13 to 0.09) Epidural saline injection
−0.05 (−0.17 to 0.06) −0.12 (−0.23 to −0.00) −0.05 (−0.16 to 0.06) Epidural steroid injection
Adjusted analysis†
0.01 (−1.06 to 0.13) −0.05 (−0.16 to 0.06) −0.01 (−0.13 to 0.10) Epidural saline injection
−0.05 (−1.62 to 0.07) −0.11 (0.22 to 0.00) −0.04 (−0.15 to 0.07) Epidural steroid injection
Data based on mixed model analysis with sham group as reference.
*Analysis adjusted for baseline values.
†Analysis adjusted for duration of leg pain, back pain, and sick leave.
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RESEARCHTable 6| Estimated differences in fear avoidance beliefs between epidural injection groups and sham group at follow-up
Difference (95% confidence intervals) at follow-up
Analysis 52 weeks 12 weeks 6 weeks
FABQ regarding physical activity
−0.24 (−2.69 to 2.21) −2.10 (−4.66 to −4.5) −0.24 (−2.69 to 2.21) Epidural saline injection
0.60 (−1.84 to 3.03) −0.67 (−3.22 to 1.87) 0.60 (−1.84 to 3.03) Epidural steroid injection
FABQ regarding work
0.72 (−3.10 to 4.55) 0.47 (−3.51 to 4.44) 0.72 (−3.10 to 4.55) Epidural saline injection
2.31 (−1.48 to 6.11) 2.40 (−1.55 to 6.34) 2.31 (−1.48 to 6.11) Epidural steroid injection
FABQ=fear avoidance beliefs questionnaire. Data based on mixed model analysis with sham group as reference.
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RESEARCHTable 7| Use of pain relief medication at 6 week follow-up
Caudal epidural steroid group Caudal epidural saline group Sham group Drug
9 (24.3) 7 (20.0) 9 (24.3) Paracetamol
6 (16.2) 4 (11.4) 2 (5.4) Non-steroidal anti-inflammatory drugs
3 (8.1) 6 (17.1) 4 (10.8) Morphine
Data are number (%) of patients.
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RESEARCHFigures
Fig 1 Flow of participants in study
Fig 2 Mean Oswestry disability index score at follow-up
Fig 3 Mean visual analogue scale score for leg pain at follow-up
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RESEARCHFig 4 Mean visual analogue scale score for back pain at follow-up
Fig 5 Repeated measurement of mean score for European quality of life measure
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